TAR-200 Leads to Durable Responses in Bacillus Calmette–Guérin-Unresponsive NMIBC
Amer. Urol. Assn. #AUA24 #AUA2024 #NMIBC #blcsm #MedTwitter #oncology
onclive.com/view/tar-200-l…

Impressive results presented by Joe Jacob MD, MCR at #AUA2024 from SunRISE-1 trial showing 82.8% CR rate at anytime and 12mo DOR 74.6%. Well tolerated. Andrea Necchi Hussein Sweiti, MD IBCG Bladder Cancer Advocacy Network

Great presentation by Dr Jacob Joe Jacob MD, MCR

Great to see the updated SunRISe-1 data being presented at #AUA24 . prnewswire.com/news-releases/…

To solve health challenges around the world, #JNJ is focused on connecting the best of Health&Care. See the impact we're making for every provider and patient. #MyCompany bit.ly/4d9hYdn

Amazing trip to Brazil 🇧🇷 visiting some incredible cancer centers partnering with J&J Innovative Medicine in our shared mission to get in front of cancer! Spent time with our local team discussing the innovation’s we are pioneering at JNJ! #MyCompany #GettingInFrontofCancer

On #TransDayOfVisibility I stand with the trans community. I celebrate the resilience, strength and contributions of transgender individuals. 🌈✨ We should all affirm that everyone deserves dignity, respect and equal rights. 🏳️‍⚧️💙 #TransVisibilityDay #EqualityForAll

Happy to share that the FDA has granted Priority Review for the PERSEUS study. This is another meaningful step forward in advancing treatment options for patients with newly diagnosed disease.
#MyCompany #JNJOncology

Great to hear the patient voice and have a patient advocate speaking loudly in the #ELCC24 symposium here in Prague. Her ask was empathy and repetition in sharing information!

Excited to be at a symposium here at #ELCC24 . So important to use the right diagnostics to treat all patients with #EGFRm #NSCLC ! Great presentation being led by ⁦Umberto Malapelle⁩.

My team at J&J Innovative Medicine is sharing data at #ELCC24 , reinforcing the potential of our innovative targeted therapy. These latest findings demonstrate our commitment to advancing the science of #LungCancer through our robust clinical program: bit.ly/3wZVfzK

Amazing meeting for health advocates to attend.

Love the butterfly theme here at #ELCC24 . Very much a favorite of mine! #MyCompany

Great to be attending one of the opening mini oral presentations sessions here at #ELCC24 . Even better to be hearing ⁦Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ⁩ discussing the presentations! #LungCancer . #MyCompany

Calling health advocates: Applications are now open for the one-of-a-kind HealtheVoices annual conference. Apply by March 25 for the opportunity to gather with fellow advocates for a weekend of learning and connection: bit.ly/3PrNWqO #HealtheVoices24

I am humbled to work with patients and patient advocates. I had a chance to talk with Jill Feldman during a meeting with my J&J Innovative Medicine colleagues on the importance of their voice. Jill, you inspire me! We hold your voice and lived experience close in all we do. #MyCompany

Love this! We have more to do! #MyCompany

egfrroutes.com

Excited to be heading to #ELCC24 and the opportunity to listen to the latest #lungcancer research. We have more to do and my colleagues and I Johnson & Johnson Innovation are committed to working to advance new treatment for patients. #MyCompany

Great to see the positive 11-0 vote today at the ODAC meeting. The voices in the Open Public Hearing were very impactful, in particular @MyelomaTeacher - Cindy Chmielewski, Yelak Biru, Surbhi Sidana, MD and Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰. #MyCompany

prnewswire.com/news-releases/…